KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals has reported Long-Term Deferred Tax over the past 3 years, most recently at $391.9 million for Q2 2019.

  • Quarterly results put Long-Term Deferred Tax at $391.9 million for Q2 2019, up 4.86% from a year ago — trailing twelve months through Jun 2019 was $391.9 million (up 4.86% YoY), and the annual figure for FY2018 was $373.2 million, up 41454.45%.
  • Long-Term Deferred Tax for Q2 2019 was $391.9 million at Amneal Pharmaceuticals, up from $382.9 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for AMRX hit a ceiling of $391.9 million in Q2 2019 and a floor of $898000.0 in Q4 2017.
  • Median Long-Term Deferred Tax over the past 3 years was $373.4 million (2018), compared with a mean of $314.8 million.
  • Biggest five-year swings in Long-Term Deferred Tax: surged 41454.45% in 2018 and later grew 4.86% in 2019.
  • Amneal Pharmaceuticals' Long-Term Deferred Tax stood at $898000.0 in 2017, then surged by 41454.45% to $373.2 million in 2018, then increased by 5.02% to $391.9 million in 2019.
  • The last three reported values for Long-Term Deferred Tax were $391.9 million (Q2 2019), $382.9 million (Q1 2019), and $373.2 million (Q4 2018) per Business Quant data.